EUVIMEDEUVIMED entdecken
Crossref

Adeno-associated virus (AAV) mediated advanced therapeutic interventions for inherited and non-inherited cardiac disorders

Indu Singh, Anil Kumar, Awdhesh Kumar Chaudhary, Jasbir Dalal, Anusha Sharma, Juhi Sharma, Arun Ratn, Megh Singh Dhakad, Divakar Sharma

Journal of the Renin-Angiotensin-Aldosterone System · 2026-03 · 27

DOI: 10.1177/14703203261437332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Renin-Angiotensin-Aldosterone System, online erschienen am 01.04.2026. Verfasst von Indu Singh und 8 weiteren Autor:innen. Die Arbeit nennt 255 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cardiovascular diseases remain the leading cause of global morbidity and mortality, driven by a complex interplay of inherited and acquired factors that limit the long-term effectiveness of conventional pharmacological, surgical, and device-based therapies. Recent advances in gene therapy have positioned adeno-associated virus (AAV) vectors as a promising platform for addressing the molecular determinants of both inherited and non-inherited cardiac disorders. Owing to their favourable safety profile, low pathogenicity, sustained transgene expression, and broad tissue tropism, AAV vectors have evolved as the most comprehensively evaluated viral delivery system in cardiovascular gene therapy.

Method

This classical review was compiled after a comprehensive literature search of major scientific databases, including PubMed, Scopus, and Web of Science, using keywords related to adeno-associated virus, therapies, inherited and non-inherited cardiac disorders. This review provides a comprehensive synthesis of the biological properties of AAV vectors, with emphasis on serotype-specific cardiac tropism, receptor usage, immunogenicity, and durability of gene expression. We critically assess preclinical and clinical evidence supporting AAV-mediated gene delivery across a spectrum of cardiac conditions, including heart failure, cardiomyopathies, ischemic heart disease, and inherited arrhythmias, highlighting both therapeutic successes and translational limitations.

Conclusions

This review highlights the current delivery strategies, genetic cargoes, and emerging genome-editing approaches, which are discussed in the context of efficacy and safety. Key challenges-such as pre-existing immunity, dose-dependent toxicity, off-target transduction, manufacturing scalability, regulatory constraints, and clinical trial design-are analysed to delineate barriers to widespread clinical adoption. Finally, we outline future directions focused on rational capsid engineering, tissue-specific targeting, improved manufacturing pipelines, and optimized clinical strategies required to advance AAV-based gene therapy toward durable and accessible treatments for cardiac diseases.

Zitieren

APA

Singh, I., Kumar, A., Chaudhary, A. K., Dalal, J., Sharma, A., Sharma, J., Ratn, A., Dhakad, M. S., & Sharma, D. (2026). Adeno-associated virus (AAV) mediated advanced therapeutic interventions for inherited and non-inherited cardiac disorders. Journal of the Renin-Angiotensin-Aldosterone System, 27. https://doi.org/10.1177/14703203261437332

Vancouver

Singh I, Kumar A, Chaudhary AK, Dalal J, Sharma A, Sharma J, et al. Adeno-associated virus (AAV) mediated advanced therapeutic interventions for inherited and non-inherited cardiac disorders. Journal of the Renin-Angiotensin-Aldosterone System. 2026;27. doi:10.1177/14703203261437332

BibTeX
@article{Singh2026,
  author = {Singh, Indu and Kumar, Anil and Chaudhary, Awdhesh Kumar and Dalal, Jasbir and Sharma, Anusha and Sharma, Juhi and Ratn, Arun and Dhakad, Megh Singh and Sharma, Divakar},
  title = {Adeno-associated virus (AAV) mediated advanced therapeutic interventions for inherited and non-inherited cardiac disorders},
  journal = {Journal of the Renin-Angiotensin-Aldosterone System},
  year = {2026},
  volume = {27},
  doi = {10.1177/14703203261437332}
}
Kostenlos starten →